IN2014CH00390A - - Google Patents

Download PDF

Info

Publication number
IN2014CH00390A
IN2014CH00390A IN390CH2014A IN2014CH00390A IN 2014CH00390 A IN2014CH00390 A IN 2014CH00390A IN 390CH2014 A IN390CH2014 A IN 390CH2014A IN 2014CH00390 A IN2014CH00390 A IN 2014CH00390A
Authority
IN
India
Prior art keywords
neu
peptide
her2
cellular immunity
provides
Prior art date
Application number
Other languages
English (en)
Inventor
Katsuyuki Okubo
Yoshiki Maeda
takuya Shishido
Daisuke Asari
Arimichi Okazaki
Kyohei Matsushita
Wenjing Li
Mitsuhiko Hori
Haruo Sugiyama
Original Assignee
Nitto Denko Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitto Denko Corp filed Critical Nitto Denko Corp
Publication of IN2014CH00390A publication Critical patent/IN2014CH00390A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • A61K39/001102Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103Receptors for growth factors
    • A61K39/001106Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/06Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/70Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/54Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/80Vaccine for a specifically defined cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
IN390CH2014 2013-02-05 2014-01-29 IN2014CH00390A (enrdf_load_stackoverflow)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2013020799 2013-02-05

Publications (1)

Publication Number Publication Date
IN2014CH00390A true IN2014CH00390A (enrdf_load_stackoverflow) 2015-07-31

Family

ID=50028736

Family Applications (1)

Application Number Title Priority Date Filing Date
IN390CH2014 IN2014CH00390A (enrdf_load_stackoverflow) 2013-02-05 2014-01-29

Country Status (8)

Country Link
US (1) US20140220100A1 (enrdf_load_stackoverflow)
EP (1) EP2762158A1 (enrdf_load_stackoverflow)
JP (1) JP2014169278A (enrdf_load_stackoverflow)
KR (1) KR20140100415A (enrdf_load_stackoverflow)
CN (1) CN103961696A (enrdf_load_stackoverflow)
CA (1) CA2840997A1 (enrdf_load_stackoverflow)
IN (1) IN2014CH00390A (enrdf_load_stackoverflow)
RU (1) RU2014102938A (enrdf_load_stackoverflow)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103961307B (zh) 2013-02-05 2019-11-29 日东电工株式会社 经皮给予用wt1肽癌症疫苗组合物
CN103961305B (zh) * 2013-02-05 2019-10-18 日东电工株式会社 经皮给予用wt1肽癌症疫苗带状制剂
EP3202417A4 (en) * 2014-10-02 2018-04-25 Nitto Denko Corporation Vaccine pharmaceutical composition for transdermal administration
ES2980430T3 (es) * 2019-10-24 2024-10-01 Lts Lohmann Therapie Systeme Ag Sistema terapéutico transdérmico para la administración transdérmica de fingolimod

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
AU2002252378B2 (en) * 2001-03-19 2007-10-18 Intercell Usa, Inc. Transcutaneous immunostimulation
US20050215501A1 (en) * 2003-10-24 2005-09-29 Coley Pharmaceutical Group, Inc. Methods and products for enhancing epitope spreading
AU2005221717B2 (en) 2004-03-15 2010-08-05 Karagen Pharmaceuticals, Inc. Method for stimulating the immune, inflammatory or neuroprotective response
DE102004049223A1 (de) 2004-10-08 2006-04-20 Johannes-Gutenberg-Universität Mainz Zubereitung zum Impfen, Impfverfahren und Verwendung einer Impf-Zubereitung
CA2523032A1 (en) * 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
JP2009544291A (ja) * 2006-07-25 2009-12-17 フォージー ヴァクシンズ ピーティーワイ エルーティーディー ムチン1(muc1)t細胞エピトープ由来ペプチド含有癌ワクチン
US20080112974A1 (en) 2006-09-08 2008-05-15 Duotol Ab Method for inducing mucosal humoral and cell-mediated immune responses by sublingual administration of antigens
EP2722336A1 (en) * 2007-06-01 2014-04-23 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Vaccine for the prevention of breast cancer relapse
JP5661735B2 (ja) * 2009-04-01 2015-01-28 ユニバーシティ オブ マイアミ ワクチン組成物及びその使用方法
CN102475886A (zh) * 2010-11-29 2012-05-30 南开大学 新型抗乳腺癌多肽疫苗

Also Published As

Publication number Publication date
RU2014102938A (ru) 2015-08-10
EP2762158A1 (en) 2014-08-06
KR20140100415A (ko) 2014-08-14
JP2014169278A (ja) 2014-09-18
US20140220100A1 (en) 2014-08-07
CN103961696A (zh) 2014-08-06
CA2840997A1 (en) 2014-08-05

Similar Documents

Publication Publication Date Title
CY1120862T1 (el) Παραγοντες επαγωγης αποπτωσης για τη θεραπευτικη αγωγη καρκινου και ανοσων και αυτοανοσων ασθενειων
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
IN2014CH00396A (enrdf_load_stackoverflow)
PH12018501043A1 (en) Site specific her2 antibody drug conjugates
IN2014CH00391A (enrdf_load_stackoverflow)
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
PH12016501411A1 (en) Bifunctional cytotoxic agents
PH12017500002A1 (en) Anti-cdh6 antibody drug conjugates
MX2016004570A (es) Uso de inhibidores del bromodominio de cbp/ep300 para la inmunoterapia del cáncer.
CL2015002472A1 (es) Como inhibidores de mutant idh-yl-oxazolidin-2-onas 3-pirimidin-4.
MX2016007063A (es) Peptidos terapeuticos.
PH12015501902A1 (en) Antibody drug conjugates
CL2015002628A1 (es) Compuestos de heteroarilo y sus usos.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
CY1117214T1 (el) Συνθεση για ελεγχομενη διεγερση των ωοθηκων
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
IN2014CH00393A (enrdf_load_stackoverflow)
IN2014CH00395A (enrdf_load_stackoverflow)
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MY191539A (en) Streptococcal vaccine
MX383966B (es) Composiciones y métodos mejorados para la entrega viral de neoepítopos y usos de estos.
MX2016005285A (es) Conjugados de somatostatina y sus analagos.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
PH12017500853B1 (en) Cd44v6-derived cyclic peptides for treating cancers and angionesesis related diseases